Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
CONCLUSIONS Taken together, we concluded that metformin exhibits anticancer effects and Cyr61 acts as a direct target for metformin in ovarian cancer cells.
PMID: 30171812 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
More News: Biomedical Science | Cancer | Cancer & Oncology | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Metformin | Ovarian Cancer | Ovaries | Research | Science | Study | Women